Check-Cap Ltd. (CHEK)

$2.9

-0.94 (-24.48%)
Rating:
Recommendation:
Buy
Symbol CHEK
Price $2.9
Beta 0.369
Volume Avg. 0.03M
Market Cap 16.891M
Shares () -
52 Week Range 2.9-17.8
1y Target Est -
DCF Unlevered CHEK DCF ->
DCF Levered CHEK LDCF ->
ROE -67.29% Strong Sell
ROA -65.27% Strong Sell
Operating Margin -
Debt / Equity 9.51% Neutral
P/E -13.62 Strong Sell
P/B 0.34 Neutral
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest CHEK news


Mr. Alex Ovadia
Healthcare
Diagnostics & Research
NASDAQ Capital Market

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.